Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Atara Biotherapeutics, Inc.ATRA · Entity 6828 | EVP, Chief Legal Officer | August 16, 2024 | August 20, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Atara Biotherapeutics, Inc.
Report date August 16, 2024 · Filed August 20, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 27,108 |
Reported balance
After 2024-08-16 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2024-08-16 · Sale · Disposed 877 · Balance 27,108 F1: Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement. F2: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on August 16, 2024 and August 19, 2024 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees. F3: This amount includes 4,507 shares purchased under the Issuer's Employee Stock Purchase Plan on May 31, 2024, and reflects the 1:25 reverse stock split effected by the Issuer on June 20, 2024. |
| Common StockSEC Table I · non-derivative | Direct | 26,916 |
Reported balance
After 2024-08-16 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2024-08-16 · Sale · Disposed 192 · Balance 26,916 F1: Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement. F2: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on August 16, 2024 and August 19, 2024 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees. |
| Common StockSEC Table I · non-derivative | Direct | 26,827 |
Reported balance
After 2024-08-16 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2024-08-16 · Sale · Disposed 89 · Balance 26,827 F1: Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement. F2: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on August 16, 2024 and August 19, 2024 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement.
F2: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on August 16, 2024 and August 19, 2024 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees.
F3: This amount includes 4,507 shares purchased under the Issuer's Employee Stock Purchase Plan on May 31, 2024, and reflects the 1:25 reverse stock split effected by the Issuer on June 20, 2024.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ACELYRIN, Inc.
Report date May 21, 2025 · Filed May 23, 2025
Section 16 reporting ended · disclosed 2025-05-23. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-05-21 transaction · row 1
1 source rowRow 1 · 2025-05-21 · Disposition to issuer · Disposed 121,587 · Balance 0 F1: On February 6, 2025, ACELYRIN, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (as amended on April 20, 2025, the "Merger Agreement") with Alumis, Inc., a Delaware corporation ("Parent"), and Arrow Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each share of common stock, par value $0.00001 per share, of the Company issued and outstanding was converted into the right to receive 0.4814 (the "Exchange Ratio") shares of voting common stock of Parent, par value $0.0001 per share ("Parent Common Stock"), and cash in lieu of any fractional shares. F2: (Continued from Footnote 1) Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unvested restricted stock unit ("RSU") immediately prior to the Effective Time was assumed by Parent and converted into an RSU award with respect to a number of shares of Parent Common Stock equal to (i) the total number of shares subject to the RSU immediately prior to the Effective Time multiplied by (ii) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share. At the Effective Time, each outstanding and vested RSU immediately prior the Effective Time, including any RSU that became vested as a result of the Merger, was cancelled and converted into the right to receive the number of shares of Parent Common Stock equal to (i) the total number of shares subject to the RSU immediately prior to the Effective Time multiplied by (ii) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.73 · Expires 2034-11-24 | Direct | 0 |
Reported balance
After 2025-05-21 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-05-21 · Disposition to issuer · Disposed 525,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per share exercise price of $18.00 or less was assumed by Parent and converted into an option to purchase a number of shares of Parent Common Stock equal to (i) the number of shares subject to the option immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, which stock option shall have an exercise price equal to (i) the per share exercise price for shares subject to the corresponding Company stock option immediately prior to the Effective Time, divided by (ii) the Exchange Ratio, rounded up to the nearest whole cent. F3: 1/4 of the shares subject to the option vest on November 13, 2025, and 1/48 of the shares subject to the option vests in equal monthly installments thereafter, subject to the Reporting Person's continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: On February 6, 2025, ACELYRIN, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (as amended on April 20, 2025, the "Merger Agreement") with Alumis, Inc., a Delaware corporation ("Parent"), and Arrow Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each share of common stock, par value $0.00001 per share, of the Company issued and outstanding was converted into the right to receive 0.4814 (the "Exchange Ratio") shares of voting common stock of Parent, par value $0.0001 per share ("Parent Common Stock"), and cash in lieu of any fractional shares.
F2: (Continued from Footnote 1) Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unvested restricted stock unit ("RSU") immediately prior to the Effective Time was assumed by Parent and converted into an RSU award with respect to a number of shares of Parent Common Stock equal to (i) the total number of shares subject to the RSU immediately prior to the Effective Time multiplied by (ii) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share. At the Effective Time, each outstanding and vested RSU immediately prior the Effective Time, including any RSU that became vested as a result of the Merger, was cancelled and converted into the right to receive the number of shares of Parent Common Stock equal to (i) the total number of shares subject to the RSU immediately prior to the Effective Time multiplied by (ii) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share.
F3: 1/4 of the shares subject to the option vest on November 13, 2025, and 1/48 of the shares subject to the option vests in equal monthly installments thereafter, subject to the Reporting Person's continued service.
F4: Pursuant to the Merger Agreement, at the Effective Time each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per share exercise price of $18.00 or less was assumed by Parent and converted into an option to purchase a number of shares of Parent Common Stock equal to (i) the number of shares subject to the option immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, which stock option shall have an exercise price equal to (i) the per share exercise price for shares subject to the corresponding Company stock option immediately prior to the Effective Time, divided by (ii) the Exchange Ratio, rounded up to the nearest whole cent.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 21, 2025 Filed May 23, 2025 16:10 UTC | ACELYRIN, Inc. SLRN · Entity 79310 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 525,000 | Not disclosed Strike: $4.73 | Not disclosed |
DisclosureSEC source: 0001962918-25-000064 · wk-form4_1748031014.xml · derivative · entry 2 Murugan Amar · CIK 0001809916 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 525,000 shares Expires 2034-11-24 F4 · price: Pursuant to the Merger Agreement, at the Effective Time each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per share exercise price of $18.00 or less was assumed by Parent and converted into an option to purchase a number of shares of Parent Common Stock equal to (i) the number of shares subject to the option immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, which stock option shall have an exercise price equal to (i) the per share exercise price for shares subject to the corresponding Company stock option immediately prior to the Effective Time, divided by (ii) the Exchange Ratio, rounded up to the nearest whole cent. F3 · derivative.exercise_date: 1/4 of the shares subject to the option vest on November 13, 2025, and 1/48 of the shares subject to the option vests in equal monthly installments thereafter, subject to the Reporting Person's continued service. Read SEC document |
| May 21, 2025 Filed May 23, 2025 16:10 UTC | ACELYRIN, Inc. SLRN · Entity 79310 | Disposition to issuerCommon Stock | 121,587 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001962918-25-000064 · wk-form4_1748031014.xml · nonDerivative · entry 1 Murugan Amar · CIK 0001809916 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: On February 6, 2025, ACELYRIN, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (as amended on April 20, 2025, the "Merger Agreement") with Alumis, Inc., a Delaware corporation ("Parent"), and Arrow Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each share of common stock, par value $0.00001 per share, of the Company issued and outstanding was converted into the right to receive 0.4814 (the "Exchange Ratio") shares of voting common stock of Parent, par value $0.0001 per share ("Parent Common Stock"), and cash in lieu of any fractional shares. F2 · price: (Continued from Footnote 1) Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unvested restricted stock unit ("RSU") immediately prior to the Effective Time was assumed by Parent and converted into an RSU award with respect to a number of shares of Parent Common Stock equal to (i) the total number of shares subject to the RSU immediately prior to the Effective Time multiplied by (ii) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share. At the Effective Time, each outstanding and vested RSU immediately prior the Effective Time, including any RSU that became vested as a result of the Merger, was cancelled and converted into the right to receive the number of shares of Parent Common Stock equal to (i) the total number of shares subject to the RSU immediately prior to the Effective Time multiplied by (ii) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share. Read SEC document |
| March 17, 2025 Filed Mar 19, 2025 18:06 UTC | ACELYRIN, Inc. SLRN · Entity 79310 | SaleCommon Stock | 3,913 | $2.74 | $10,737.27 |
DisclosureSEC source: 0001962918-25-000029 · wk-form4_1742422007.xml · nonDerivative · entry 1 Murugan Amar · CIK 0001809916 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 121,587 F1 · kind: The sale reported on this Form 4 was effected pursuant to the Issuer's policy requiring sell-to-cover to satisfy certain tax obligations of the Reporting Person incurred with the vesting and settlement of certain Restricted Stock Units, and does not represent a discretionary sale by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices no more than $2.76 and no less than $2.71, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 23, 2025 Filed Jan 24, 2025 17:58 UTC | ACELYRIN, Inc. SLRN · Entity 79310 | GrantCommon Stock | 125,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001962918-25-000005 · wk-form4_1737759494.xml · nonDerivative · entry 1 Murugan Amar · CIK 0001809916 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,500 F1 · shares: Represents Restricted Stock Units (RSUs) that vest in twelve (12) equal quarterly installments over three (3) years, beginning on March 15, 2025, and continuing on June 15, September 15, and December 15, 2025, and on the same dates in each subsequent year, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| November 25, 2024 Filed Nov 27, 2024 17:17 UTC | ACELYRIN, Inc. SLRN · Entity 79310 | GrantEmployee Stock Option (right to buy) · Derivative | 525,000 | $0.00 Strike: $4.73 | $0.00 |
DisclosureSEC source: 0001962918-24-000134 · wk-form4_1732745834.xml · derivative · entry 1 Murugan Amar · CIK 0001809916 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 525,000 Underlying: Common Stock · 525,000 shares Expires 2034-11-24 F1 · derivative.exercise_date: 1/4 of the shares subject to the option vest on November 13, 2025, and 1/48 of the shares subject to the option vests in equal monthly installments thereafter, subject to the Reporting Person's continued service. Read SEC document |
| August 16, 2024 Filed Aug 20, 2024 18:27 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 89 | $6.63 | $590.16 |
DisclosureSEC source: 0000905148-24-002304 · form4.xml · nonDerivative · entry 3 Murugan Amar · CIK 0001809916 · EVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,827 F1 · kind: Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on August 16, 2024 and August 19, 2024 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees. Read SEC document |
| August 16, 2024 Filed Aug 20, 2024 18:27 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 192 | $6.63 | $1,272.96 |
DisclosureSEC source: 0000905148-24-002304 · form4.xml · nonDerivative · entry 2 Murugan Amar · CIK 0001809916 · EVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,916 F1 · kind: Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on August 16, 2024 and August 19, 2024 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees. Read SEC document |
| August 16, 2024 Filed Aug 20, 2024 18:27 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 877 | $6.63 | $5,813.63 |
DisclosureSEC source: 0000905148-24-002304 · form4.xml · nonDerivative · entry 1 Murugan Amar · CIK 0001809916 · EVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,108 F1 · kind: Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on August 16, 2024 and August 19, 2024 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees. F3 · balance_after: This amount includes 4,507 shares purchased under the Issuer's Employee Stock Purchase Plan on May 31, 2024, and reflects the 1:25 reverse stock split effected by the Issuer on June 20, 2024. Read SEC document |
| May 16, 2024 Filed May 20, 2024 20:33 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 32,401 | $0.62 | $19,991.42 |
DisclosureSEC source: 0000905148-24-001559 · form4.xml · nonDerivative · entry 1 Murugan Amar · CIK 0001809916 · EVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 695,120 F1 · kind: Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on May 16, 2024 and May 17, 2024 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees. Read SEC document |
| March 04, 2024 Filed Mar 6, 2024 18:18 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 10,044 | $0.72 | $7,231.68 |
DisclosureSEC source: 0000905148-24-000909 · form4.xml · nonDerivative · entry 1 Murugan Amar · CIK 0001809916 · EVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 727,521 F1 · kind: Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on March 4, 2024 and March 5, 2024 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees. Read SEC document |
| January 08, 2024 Filed Jan 9, 2024 16:40 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantCommon Stock | 475,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-24-000113 · form4.xml · nonDerivative · entry 1 Murugan Amar · CIK 0001809916 · EVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 737,565 F1 · shares: These restricted stock units vest as to 1/8th of the total number of shares (rounded down to the next whole number of shares) on the second Quarterly Vesting Date (as defined below) following January 8, 2024, and as to 1/8th of the total number of shares (rounded down to the next whole number of shares) on the next seven Quarterly Vesting Dates, such that all of the shares shall be vested on the last Quarterly Vesting Date, subject to the reporting person's continuous service. "Quarterly Vesting Date" means March 1, May 15, August 15, and November 15 of each year, provided that if such date falls on a weekend or holiday, the Quarterly Vesting Date shall be the first business day after such date. F2 · balance_after: Includes 5,481 shares purchased under the Issuer's Employee Stock Purchase Plan on November 30, 2023. Read SEC document |
| November 16, 2023 Filed Nov 20, 2023 17:30 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 8,307 | $0.39 | $3,231.42 |
DisclosureSEC source: 0000905148-23-001511 · form4.xml · nonDerivative · entry 1 Murugan Amar · CIK 0001809916 · EVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 257,084 F1 · kind: Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on November 16, 2023 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employee. Read SEC document |
| August 16, 2023 Filed Aug 18, 2023 18:25 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 3,622 | $1.65 | $5,987.17 |
DisclosureSEC source: 0001140361-23-040563 · form4.xml · nonDerivative · entry 2 Murugan Amar · CIK 0001809916 · EVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 265,391 F1 · kind: Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on August 16, 2023 and August 17, 2023 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employee. Read SEC document |
| August 16, 2023 Filed Aug 18, 2023 18:25 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 5,050 | $1.65 | $8,342.60 |
DisclosureSEC source: 0001140361-23-040563 · form4.xml · nonDerivative · entry 1 Murugan Amar · CIK 0001809916 · EVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 269,013 F1 · kind: Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on August 16, 2023 and August 17, 2023 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employee. F3 · balance_after: Includes 3,118 shares purchased under the Issuer's Employee Stock Purchase Plan on May 31, 2023. Read SEC document |
| May 16, 2023 Filed May 18, 2023 20:17 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 985 | $2.04 | $2,007.43 |
DisclosureSEC source: 0001140361-23-025560 · form4.xml · nonDerivative · entry 2 Murugan Amar · CIK 0001809916 · EVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 270,945 F1 · kind: Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on May 16, 2023 and May 17, 2023 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employee. Read SEC document |
| May 16, 2023 Filed May 18, 2023 20:17 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 7,404 | $2.04 | $15,081.95 |
DisclosureSEC source: 0001140361-23-025560 · form4.xml · nonDerivative · entry 1 Murugan Amar · CIK 0001809916 · EVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 271,930 F1 · kind: Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on May 16, 2023 and May 17, 2023 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employee. Read SEC document |
| March 02, 2023 Filed Mar 6, 2023 18:48 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 4,221 | $3.63 | $15,309.57 |
DisclosureSEC source: 0001567619-23-004539 · doc1.xml · nonDerivative · entry 1 Murugan Amar · CIK 0001809916 · SVP, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 279,334 F1 · kind: Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations in connection with the vesting of previously granted restricted stock units. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on March 2, 2023 and March 3, 2023 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employee. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 17:15 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantEmployee Stock Option (Right to Buy) · Derivative | 349,593 | $0.00 Strike: $3.91 | $0.00 |
DisclosureSEC source: 0001140361-23-010097 · form4.xml · derivative · entry 2 Murugan Amar · CIK 0001809916 · SVP, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 349,593 Underlying: Common Stock · 349,593 shares Expires 2033-02-28 F3 · derivative.exercise_date: 1/36th of the shares subject to the stock option vest and become exercisable each month, with the initial installment vesting on April 1, 2023, subject to the reporting person's continuous service. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 17:15 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantCommon Stock | 155,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-010097 · form4.xml · nonDerivative · entry 1 Murugan Amar · CIK 0001809916 · SVP, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 283,555 F1 · shares: These restricted stock units vest in 12 equal quarterly installments on each Company Quarterly Vesting Date (as defined below), with the initial installment vesting on May 15, 2023, subject to the reporting person's continuous service. "Company Quarterly Vesting Date" means March 1, May 15, August 15 and November 15 of each year. F2 · balance_after: Includes 594 shares purchased under the Issuer's Employee Stock Purchase Plan on November 30, 2022. Read SEC document |
| November 16, 2022 Filed Nov 18, 2022 20:13 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 3,612 | $4.49 | $16,217.88 |
DisclosureSEC source: 0001140361-22-042379 · form4.xml · nonDerivative · entry 1 Murugan Amar · CIK 0001809916 · SVP, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,586 F1 · kind: Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations in connection with the vesting of previously granted restricted stock units. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on November 16, 2022 and November 17, 2022 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employee. Read SEC document |
| August 16, 2022 Filed Aug 18, 2022 18:21 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 2,234 | $5.04 | $11,248.19 |
DisclosureSEC source: 0001140361-22-030299 · form4.xml · nonDerivative · entry 2 Murugan Amar · CIK 0001809916 · SVP, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,198 F1 · kind: Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations in connection with the vesting of previously granted restricted stock units. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on August 16, 2022 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employee. Read SEC document |
| August 16, 2022 Filed Aug 18, 2022 18:21 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 1,196 | $5.03 | $6,020.66 |
DisclosureSEC source: 0001140361-22-030299 · form4.xml · nonDerivative · entry 1 Murugan Amar · CIK 0001809916 · SVP, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,432 F1 · kind: Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations in connection with the vesting of previously granted restricted stock units. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on August 16, 2022 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employee. F3 · balance_after: Includes 893 shares purchased under the Issuer's Employee Stock Purchase Plan on May 31, 2022. Read SEC document |
| May 17, 2022 Filed May 19, 2022 17:20 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 906 | $5.32 | $4,817.20 |
DisclosureSEC source: 0001140361-22-019990 · form4.xml · nonDerivative · entry 2 Murugan Amar · CIK 0001809916 · SVP, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,735 F1 · kind: Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations in connection with the vesting of previously granted restricted stock units. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on May 17, 2022 and May 18, 2022 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employee. Read SEC document |
| May 17, 2022 Filed May 19, 2022 17:20 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 2,317 | $5.32 | $12,317.17 |
DisclosureSEC source: 0001140361-22-019990 · form4.xml · nonDerivative · entry 1 Murugan Amar · CIK 0001809916 · SVP, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,641 F1 · kind: Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations in connection with the vesting of previously granted restricted stock units. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on May 17, 2022 and May 18, 2022 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employee. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 19:02 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantEmployee Stock Option (Right to Buy) · Derivative | 97,398 | $0.00 Strike: $10.21 | $0.00 |
DisclosureSEC source: 0001140361-22-007763 · form4.xml · derivative · entry 4 Murugan Amar · CIK 0001809916 · SVP, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,398 Underlying: Common Stock · 97,398 shares Expires 2032-02-28 F4 · derivative.exercise_date: 1/48th of the shares subject to the stock option vest and become exercisable each month with the initial installment vesting on April 1, 2022, subject to the reporting person's continuous service. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 19:02 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 1,112 | $9.86 | $10,959.87 |
DisclosureSEC source: 0001140361-22-007763 · form4.xml · nonDerivative · entry 3 Murugan Amar · CIK 0001809916 · SVP, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,958 F2 · kind: Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations in connection with the vesting of previously granted restricted stock units. F3 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on March 1, 2022 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employee. F5 · balance_after: Includes 181 shares purchased under the Issuer's Employee Stock Purchase Plan on November 30, 2021. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 19:02 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 1,465 | $9.86 | $14,440.51 |
DisclosureSEC source: 0001140361-22-007763 · form4.xml · nonDerivative · entry 2 Murugan Amar · CIK 0001809916 · SVP, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,070 F2 · kind: Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations in connection with the vesting of previously granted restricted stock units. F3 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on March 1, 2022 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employee. F5 · balance_after: Includes 181 shares purchased under the Issuer's Employee Stock Purchase Plan on November 30, 2021. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 19:02 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantCommon Stock | 51,814 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-22-007763 · form4.xml · nonDerivative · entry 1 Murugan Amar · CIK 0001809916 · SVP, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,535 F1 · shares: These restricted stock units vest in 16 equal quarterly installments on each Company Quarterly Vesting Date (as defined below), with the initial installment vesting on May 15, 2022, subject to the reporting person's continuous service. Company Quarterly Vesting Date means March 1, May 15, August 15 and November 15 of each year. F5 · balance_after: Includes 181 shares purchased under the Issuer's Employee Stock Purchase Plan on November 30, 2021. Read SEC document |
| November 16, 2021 Filed Nov 18, 2021 17:53 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 2,124 | $17.12 | $36,356.30 |
DisclosureSEC source: 0001567619-21-020779 · doc1.xml · nonDerivative · entry 1 Murugan Amar · CIK 0001809916 · SVP, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,540 F1 · kind: Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations in connection with the vesting of previously granted Restricted Stock Units. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on November 16, 2021 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees. The prices actually received ranged from $16.45 to $17.3823. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold on behalf of the group at each price within the range. Read SEC document |
| August 17, 2021 Filed Aug 19, 2021 19:35 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 2,080 | $12.53 | $26,066.56 |
DisclosureSEC source: 0001567619-21-016149 · doc1.xml · nonDerivative · entry 1 Murugan Amar · CIK 0001809916 · SVP, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,664 F1 · kind: Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations in connection with the vesting of previously granted Restricted Stock Units. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on August 17, 2021 and August 18, 2021 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees. Read SEC document |
| May 18, 2021 Filed May 20, 2021 16:32 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 5,681 | $14.55 | $82,658.55 |
DisclosureSEC source: 0001209191-21-034426 · doc4.xml · nonDerivative · entry 1 Murugan Amar · CIK 0001809916 · SVP, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,744 F1 · kind: Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations in connection with the vesting of previously granted Restricted Stock Units. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on May 18, 2021 and May 19, 2021 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 17:16 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantEmployee Stock Option (Right to Buy) · Derivative | 63,028 | $0.00 Strike: $17.11 | $0.00 |
DisclosureSEC source: 0001209191-21-017043 · doc4.xml · derivative · entry 2 Murugan Amar · CIK 0001809916 · SVP, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,028 Underlying: Common Stock · 63,028 shares Expires 2031-02-28 F3 · derivative.exercise_date: 1/48th of the shares subject to the stock option vest and become exercisable each month with the initial installment vesting on April 1, 2021, subject to the reporting person's continuous service. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 17:16 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantCommon Stock | 41,756 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-017043 · doc4.xml · nonDerivative · entry 1 Murugan Amar · CIK 0001809916 · SVP, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,425 F1 · shares: These restricted stock units vest in 16 equal quarterly installments on each Company Quarterly Vesting Date (as defined below), with the initial installment vesting on May 15, 2021, subject to the reporting person's continuous service. Company Quarterly Vesting Date means March 1, May 15, August 15 and November 15 of each year. F2 · balance_after: Includes 669 shares purchased pursuant to the Issuer's Employee Stock Purchase Plan on November 30, 2020. Read SEC document |
| April 20, 2020 Filed Apr 21, 2020 16:17 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantEmployee Stock Option (Right to Buy) · Derivative | 110,000 | $0.00 Strike: $8.20 | $0.00 |
DisclosureSEC source: 0001209191-20-025229 · doc4.xml · derivative · entry 2 Murugan Amar · CIK 0001809916 · SVP, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,000 Underlying: Common Stock · 110,000 shares Expires 2030-04-19 F2 · derivative.exercise_date: 25% of the shares subject to the option vest on April 20, 2021 and the remaining shares vest in equal monthly installments over the following 36 months, subject to the reporting person's continuous service. Read SEC document |
| April 20, 2020 Filed Apr 21, 2020 16:17 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantCommon Stock | 55,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-025229 · doc4.xml · nonDerivative · entry 1 Murugan Amar · CIK 0001809916 · SVP, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 F1 · shares: 25% of the shares subject to these restricted stock units ("RSUs") vest on May 15, 2021 and 1/16th of the total number shares subject to the RSUs vest on each of the next 12 Quarterly Vesting Dates (as defined below), subject to the reporting person's continuous service. Company Quarterly Vesting Date means March 1, May 15, August 15 and November 15 of each year. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.